Hype Court: peptide hype, on trial
A fictional courtroom with real facts. Each short episode puts one viral peptide claim in the dock, lets the internet make its case, and then reads the actual studies into the record. The characters are made up. The numbers aren’t. Every episode below has its verdict, the studies it cites and the full transcript.
The People vs. Copper (GHK-Cu)
Doug swears copper peptide grew his hair back. Six weeks, every night, twice on Sundays. Then the toupee testifies.
The facts read into the record
- GHK-Cu is three amino acids (glycine, histidine, lysine) bound to one copper atom. Loren Pickart first described GHK in human blood plasma in 1973, and levels fall with age.
- Most of the research is on skin: cells in a dish making more collagen, and wound-healing studies in animals.
- The hair study that gets shared tested a different molecule, AHK-Cu, on hair follicles in a dish (Pyo et al., 2007). It is not evidence that GHK-Cu regrows hair on a person.
The studies (3)
- Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver (Pickart & Thaler)Nature New Biology, 1973
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (Pickart & Margolina)International Journal of Molecular Sciences, 2018
- The effect of tripeptide-copper complex on human hair growth in vitro (Pyo et al.), the AHK-Cu hair follicle studyArchives of Pharmacal Research, 2007
Full transcript
Doug: Six weeks ago, I was completely bald. Look at me now.
The Judge: Case zero-zero-three. The People versus copper. Sir… is that your hair?
Priya (defence): Your Honour, my client rubbed copper peptide on his head every single night.
Doug: Twice on Sundays.
Marcus (prosecutor): Let’s be fair. GHK copper is real. It was found in human blood in nineteen seventy-three. Your levels drop with age. And the real research is on skin. Cells in a dish. Animal wounds.
Doug: With respect, sir… you need this more than I do.
Marcus (prosecutor): Objection. Personal.
The Judge: Sustained. …Sadly.
Marcus (prosecutor): The hair study everyone shares? A different molecule. On follicles in a dish. Not a head.
Doug: That’s a lie! It grew back!
The Judge: Skin research: real. Hair on a human head: not shown. Guilty.
Man in gym clothes: I haven’t worked out in a month. Never been fitter!
The Judge: Bailiff. I need a bigger gavel.
The People vs. BPC-157 (“the Wolverine peptide”)
Rex rips off his bandage: “Healed. Overnight.” The Crown calls its star witness. It’s a lab rat.
The facts read into the record
- Almost all BPC-157 research is in rats and cells, much of it from one research group in Zagreb, Croatia.
- The human data so far: a 2021 look-back at 16 knee-pain patients with no control group (Lee & Padgett), and a 2025 IV safety pilot in 2 healthy adults (Lee & Burgess).
- Not approved as a medicine anywhere, and prohibited in sport by WADA.
The studies (3)
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang et al.)Journal of Applied Physiology, 2011
- Intra-articular injection of BPC 157 for multiple types of knee pain (Lee & Padgett)Alternative Therapies in Health and Medicine, 2021
- Safety of intravenous infusion of BPC157 in humans: a pilot study (Lee & Burgess)Alternative Therapies in Health and Medicine, 2025
Full transcript
Rex (the defendant): Healed. Overnight.
The Judge: Case zero-zero-two. The People versus… B-P-C. And yes, Brayden. I can see you.
Priya (defence): Why am I always defending these guys?
Rex (the defendant): Because you believe in me.
Priya (defence): I really don’t.
Marcus (prosecutor): Your Honour, the internet calls the defendant the Wolverine peptide. The Crown calls its first witness.
The Judge: Let the record show… the witness is a rat.
Marcus (prosecutor): Almost all the research? Rats and cells. Mostly from one lab group in Croatia.
Priya (defence): Objection! There are human studies!
Marcus (prosecutor): Name one.
Priya (defence): Twenty twenty-one. Sixteen patients with knee pain!
Marcus (prosecutor): No control group.
Priya (defence): …And a twenty twenty-five safety pilot!
Marcus (prosecutor): With two people, Your Honour. That’s not a trial. That’s a dinner party.
The Judge: Promising in rats. Barely tested in people. Approved nowhere. Banned in sport. Guilty!
Rex (the defendant): Nooooo!
Bald man in a bathrobe: It grew back! It’s the copper!
The Judge: Not the copper peptide.
The People vs. “Reta” (retatrutide)
Brayden goes live from court: retatrutide is “basically approved.” The prosecutor agrees the science is strong. Then he reads the fine print.
The facts read into the record
- Phase 2 trial: 338 adults over 48 weeks, with large weight loss versus placebo (Jastreboff et al., New England Journal of Medicine, 2023).
- Phase 3 (TRIUMPH-1, topline May 2026): 2,339 people randomised, strong results again.
- Trial participants had doctors, set schedules and check-ups; nausea was common. It is not approved by Health Canada or the FDA.
The studies (2)
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialNew England Journal of Medicine, 2023
- Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1)Eli Lilly and Company, May 2026
Full transcript
The Judge: Case zero-zero-one. The People versus… Reta.
Brayden (the defendant): What’s up, Reta gang, we are live from court!
The Judge: Phone. Down!
Marcus (prosecutor): Your Honour, the defendant claims retatrutide is basically approved.
Brayden (the defendant): Approved by the vibes, bro.
Priya (defence): My client is… enthusiastic. But the science is real.
Marcus (prosecutor): She’s right.
Brayden (the defendant): Wait. Am I… winning?
Marcus (prosecutor): Phase two. New England Journal of Medicine, 2023. 338 adults. 48 weeks. Big weight loss versus placebo. Then May 2026. Phase three. Over two thousand people. Strong again.
Brayden (the defendant): Innocent!
Marcus (prosecutor): Sit down, Brayden. Those people had doctors. Set schedules. Check-ups. Nausea was common. And, Your Honour… it’s not approved. Anywhere.
Priya (defence): Did you read past the headline?
Brayden (the defendant): There’s more than a headline?
The Judge: The science: strong. The hype: guilty of skipping the fine print.
Bailiff: Your Honour, the next defendant is here.
The Judge: Oh no. Not B-P-C.
Get the next hype check first
One short email when a new video drops, plus updates to the Hype Leaderboard. No spam; unsubscribe anytime.
Hype Court is fiction: the characters, the court and the case are invented for comedy. The facts, numbers and studies are real and linked above. Nothing here is medical advice. All Popular Peptides products are supplied for in vitro laboratory research use only and are not for human or veterinary use.